Celgene Corporation, a biopharmaceutical company engaged in the discovery, development and commercialization of therapies, has provided financial outlook for the year ending December 31, 2013. The company expects total net product sales to be approximately $6 billion, an 11.4% year-over-year increase.
For the year 2013, REVLIMID net sales are expected to be in the range of $4.1 billion to $4.2 billion, including approximately $90 million of negative year-over-year foreign exchange impact. Adjusted diluted earnings per share, or EPS, is expected to be in the range of $5.50 to $5.60.
The company has also reaffirmed net product sales outlook for 2015 to be between $8 billion to $9 billion and adjusted diluted EPS to be between $8.00 to $9.00.
"The accomplishments of 2012 and our outlook for 2013 have positioned us with significant catalysts as we enter a new growth phase for Celgene in all three therapeutic areas of our business - hematology, oncology and inflammation and immunology," said Bob Hugin, Celgene's Chairman and CEO. "The increased visibility we now have to many of those catalysts allows us to reaffirm our 2015 targets and give new targets out to 2017."